GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: ZP-8396 | ZP8396
Compound class:
Peptide
Comment: Petrelintide (ZP8396) is a long-acting (lipidated) analogue of the anorexigenic peptide amylin [1]. It was developed by Zealand Pharma for the treatment of type 2 diabetes and obesity. Amylin analogues are proposed to provide GLP-1-like efficacy with reduced propensity for side effects.
|
| No information available. |
Summary of Clinical Use  |
| Petrelintide (ZP8396) is a clinical stage anti-obesity candidate [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05096598 | A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants | Phase 1 Interventional | Zealand Pharma | ||
| NCT05613387 | A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants | Phase 1 Interventional | Zealand Pharma | ||
| NCT06662539 | Once-weekly Petrelintide Versus Placebo for Obesity or Overweight with Co-morbidities | Phase 2 Interventional | Zealand Pharma | ||
